Montelukast (sodium)

ArtNr	HY-13315-50mg
Hersteller	MedChem Express
CAS-Nr.	151767-02-1
Menge	50 mg
Quantity options	100 mg 10 mM/1 mL 500 mg 50 mg
Kategorie	Oncology Neuroscience Neuroinflammation Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Testicular & Prostate Cancer
Typ	Inhibitors
Specific against	other
Purity	99.84
Citations	[1]Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.\|[2]William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16.\|[3]Langlois A, et al. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006;118(1):113-119.\|[4]Khan AR, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2022 Apr;59(4):780-786. Artif Cell Nanomed B. 2019 Dec;47(1):4234-4239.\|Eur J Pharmacol. 2022 May 15;923:174892.\|J Cachexia Sarcopenia Muscle. 2022 Jun 9.\|Patent. US20230404992A1.\|Adv Mater. 2024 Jun;36(24):e2311760.\|Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 27.\|Patent. US20210309696A1.\|Patent. US20230348536A1.\|SSRN. 2024 Oct 29.
Smiles	ClC1=CC2=C(C=C1)C=CC(/C=C/C3=CC([C@H](SCC4(CC(O[Na])=O)CC4)CCC5=CC=CC=C5C(C)(O)C)=CC=C3)=N2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MK0476
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Leukotriene Receptor
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	608.17
Product Description	Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research[1][2][3][4].
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)\|H2O : 50 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein
Clinical information	Launched
Isoform	LTD4/CysLT1

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.